Markets:

Overview

News

Currencies

International

Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

11.52 +0.50 (+4.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022 ↗

June 21, 2022

Upgrades

Via Benzinga

Analyst Ratings for Arvinas ↗

May 20, 2022

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022 ↗

May 09, 2022

Upgrades

Via Benzinga

Arvinas: Q1 Earnings Insights ↗

May 05, 2022

Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

What 6 Analyst Ratings Have To Say About Arvinas ↗

April 28, 2022

Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Expert Ratings For Arvinas ↗

April 06, 2022

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Via Benzinga

Arvinas Earnings Perspective: Return On Capital Employed ↗

March 01, 2022

Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter. In Q3,...

Via Benzinga

Arvinas: Q4 Earnings Insights ↗

February 28, 2022

Arvinas (NASDAQ:ARVN) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Analyst Ratings For Arvinas ↗

October 14, 2021

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within th...

Via Benzinga

Expert Ratings For Arvinas ↗

September 30, 2021

Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following ...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Where Arvinas Stands With Analysts ↗

March 01, 2022

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2...

Via Benzinga

Analyst Ratings For Arvinas ↗

September 09, 2021

Over the past 3 months, 5 analysts have published their opinion on Arvinas (NASDAQ:

Via Benzinga

3 Stocks To Double Down On In 2022 ↗

February 16, 2022

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination...

Via Benzinga

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients ↗

February 15, 2022

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗

February 10, 2022

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 ↗

January 19, 2022

Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo...

Via Benzinga

5 Stocks Insiders Are Selling ↗

December 17, 2021

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to...

Via Benzinga

Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients ↗

December 10, 2021

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or...

Via Benzinga

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗

December 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...

Via Benzinga

4 Stocks Insiders Are Selling ↗

November 16, 2021

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗

October 14, 2021

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗

September 30, 2021

Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗

September 09, 2021

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arvinas, Inc. - Common Stock (NQ:ARVN)

All News about Arvinas, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today